Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06133101 · ClinicalTrials.gov registry record · Phase 2
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
A Phase 2 study of Non-alcoholic Fatty Liver Disease, sponsored by Marialena Mouzaki.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06133101 is a Phase 2 study of Non-alcoholic Fatty Liver Disease that is actively recruiting participants, run by Marialena Mouzaki. The registered enrollment target is 44 participants, below the 189-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06133101, a Phase 2 study of Non-alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by Marialena Mouzaki.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities. The investigators do not expect any adverse endocrine or metabolomic effects from the consumption of soy isoflavones.
Conditions Studied
Interventions
- DRUG Standard Soy Milk
- DRUG 2% Fat Cow's Milk
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2024-01-15 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06133101
The ClinicalTrials.gov registry entry for NCT06133101 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (77% lower). The listed sponsor is Marialena Mouzaki, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Standard Soy Milk is the first listed.
NCT06133101 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06133101 about?
NCT06133101 is a clinical study titled "Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)". A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD...
What is the current status of trial NCT06133101?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2024-01-15. Estimated completion is 2026-06.
What conditions does trial NCT06133101 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT06133101?
The interventions under investigation include: Standard Soy Milk (DRUG), 2% Fat Cow's Milk (DRUG).
Who is sponsoring clinical trial NCT06133101?
This trial is sponsored by Marialena Mouzaki, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06133101 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
RECRUITING · Phase 2
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2b Study of GSK4532990 in Adults With NASH
ACTIVE NOT RECRUITING · Phase 2
-
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.